Menopause And HRT
Based on these findings, the USPSTF concluded that for most postmenopausal women with an intact uterus, combined estrogen and progestin had no net benefit for primary prevention of chronic conditions (D recommendation).
The researchers found that the women assigned to estradiol exhibited blunted cortisol responses to CPT compared with the women in the placebo group (P=0.017) and lesser negative effects of stress on working memory (P=0.048).
Noven announced that CombiPatch (estradiol/norethindrone acetate transdermal system) and Minivelle (estradiol transdermal system) are now readily available following a temporary product shortage.
The researchers found that during the 18-year follow-up, there were 7,489 deaths (1,088 deaths during the intervention phase and 6,401 deaths during postintervention follow-up).
The researchers recommend that women should not generally be treated with menopausal hormone therapy or tibolone following breast cancer, but should optimize lifestyle.
More women are looking toward alternatives like licorice due to, "concerns about the risk of stroke and breast cancer associated with conventional hormone," said Richard B. van Breemen, PhD, and lead author.
The data showed women with an intact uterus did not have a significantly different risk of stroke, invasive breast cancer, colorectal cancer, endometrial cancer, and pulmonary embolism/deep vein thrombosis (PE/DVT) between those who used vaginal estrogen and those who did not.
Local estrogen therapy has been shown to restore vaginal pH and resvascularize the vaginal and urethral mucosa, improving vaginal dryness and mucosal atrophy.
Intrarosa contains prasterone, an inactive precursor that is converted locally into estrogens and androgens (with minimal systemic exposure) to help restore vaginal tissue.
Firstly, NAMS reiterates that HT should be individualized for each patient and requires periodic reevaluation for risks and benefits of selected therapy.
The data showed sarcopenia was 4 times more prevalent for the high-risk alcohol drinking group vs. the low-risk alcohol drinking group (odds ratio 4.29, 95% CI: 1.87, 9.82).
The investigators found that earlier menopause was associated with increased risk of heart failure, and this link was stronger in women who had natural rather than surgical menopause.
TherapeuticsMD announced positive data for its investigational hormone therapy, TX-001HR, for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. Study findings were presented at the annual meeting of the Endocrine Society, ENDO 2017.
Prague JK, et al. "Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial"
The researchers found that the group receiving estriol gel had improvement in all aspects of vaginal health before surgery versus baseline .
The researchers found that the overall survival was strongest among premenopausal women in the highest 25OHD tertile group.
Researchers found that their evidence showed no protective association between postmenopausal HT use and AD or dementia, although they observed a reduced AD risk among those with long-term self-reported HT use.
Chronic pain patients being treated with certain opioid and non-opioid medications had significantly lower serum concentrations of free testosterone (fTe) and free estradiol (fE2), highlighting the potential endocrinologic side effects of these drugs. These were the findings of a new study published in the journal Drug Testing and Analysis.
For HIV-infected women, anti-müllerian hormone is associated with age of menopause onset, according to a study published in the January issue of the American Journal of Obstetrics & Gynecology.
Menopausal status is associated with accelerated lung function decline, according to a study published online in the American Journal of Respiratory and Critical Care Medicine.
The FDA has approved Intrarosa (prasterone; Endoceutics) for the treatment of women experiencing moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.
For women who are former hormone therapy users, risk of fracture is not increased after discontinuing therapy, according to a study published in the The Journal of Clinical Endocrinology & Metabolism.
Pfizer announced a voluntary recall of one lot of Premarin (conjugated estrogens) 1.25mg tablets due to an incorrect expiration date applied to the bottle label.
For postmenopausal women with osteoporosis, romosozumab is associated with reduced risk of vertebral fracture at 12 months